Affiliation:
1. Unit of Dermatology, Department of Medical-Surgical Science and Biotechnologies, Sapienza University of Rome, A.
Fiorini Hospital, Terracina, Latina, Italy
Abstract
Abstract:
Dupilumab is a fully humanized IgG4 monoclonal antibody, inhibiting IL-4 and IL-13
signaling, which are the main cytokines involved in type 2 inflammatory diseases. Its
introduction was a breakthrough in the treatment of moderate-to-severe atopic dermatitis, but it is
also used in other inflammatory diseases, including asthma, eosinophilic esophagitis and chronic
rhinosinusitis with nasal polyposis. Recent advances in the understanding of inflammatory
pathways have revealed that Th2-type inflammation is involved in a wider range of diseases than
previously thought. The aim of our review is to examine off-label therapeutic indications of
dupilumab, including bullous dermatoses (pemphigus, bullous pemphigoid) and alopecia areata,
and to investigate its potential applications in cancer patients on anti-PD1 therapy.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,General Medicine